ACTG Publications

TitleAuthorsDateJournalIssueVolume
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.Deeks, Steven G ; Gange, Stephen J ; Kitahata, Mari M ; Saag, Michael S ; Justice, Amy C ; Hogg, Robert S ; Eron, Joseph J ; Brooks, John T ; Rourke, Sean B ; Gill, M John ; Bosch, Ronald J ; Benson, Constance A ; Collier, Ann C ; Martin, Jeffrey N ; Klein, Marina B ; Jacobson, Lisa P ; Rodriguez, Benigno ; Sterling, Timothy R ; Kirk, Greg2009 Nov 15Clin Infect Dis1049
Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir.Ouyang, Zhengyu ; Buzon, Maria J ; Zheng, Lu ; Sun, Hong ; Yu, Xu G ; Bosch, Ronald J ; Mellors, John W ; Eron, Joseph J ; Gandhi, Rajesh T ; Lichterfeld, Mathias2015 AprOpen Forum Infect Dis22
T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.Thomas, Allison S ; Jones, Kimberley L ; Gandhi, Rajesh T ; McMahon, Deborah K ; Cyktor, Joshua C ; Chan, Dora ; Huang, Szu-Han ; Truong, Ronald ; Bosque, Alberto ; Macedo, Amanda B ; Kovacs, Colin ; Benko, Erika ; Eron, Joseph J ; Bosch, Ronald J ; Lalama, Christina M ; Simmens, Samuel ; Walker, Bruce D ; Mellors, John W ; Jones, R Brad2017 SepPLoS Pathog913
Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.Kalayjian, Robert C ; Franceschini, Nora ; Gupta, Samir K ; Szczech, Lynda A ; Mupere, Ezekiel ; Bosch, Ronald J ; Smurzynski, Marlene ; Albert, Jeffrey M2008 Feb 19AIDS422
Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort.Chow, Felicia C ; Wilson, Michael R ; Wu, Kunling ; Ellis, Ronald J ; Bosch, Ronald J ; Linas, Benjamin P2018 Jun 01AIDS932
Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.Brown, Todd T ; Smurzynski, Marlene ; Wu, Kunling ; Bosch, Ronald J ; McComsey, Grace A2009Antivir Ther614
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.Tenorio, Allan R ; Zheng, Yu ; Bosch, Ronald J ; Krishnan, Supriya ; Rodriguez, Benigno ; Hunt, Peter W ; Plants, Jill ; Seth, Arjun ; Wilson, Cara C ; Deeks, Steven G ; Lederman, Michael M ; Landay, Alan L2014 Oct 15J Infect Dis8210
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.Li, Jonathan Z ; Etemad, Behzad ; Ahmed, Hayat ; Aga, Evgenia ; Bosch, Ronald J ; Mellors, John W ; Kuritzkes, Daniel R ; Lederman, Michael M ; Para, Michael ; Gandhi, Rajesh T2016 Jan 28AIDS330
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.Meier, Angela ; Chang, J Judy ; Chan, Ellen S ; Pollard, Richard B ; Sidhu, Harlyn K ; Kulkarni, Smita ; Wen, Tom Fang ; Lindsay, Robert J ; Orellana, Liliana ; Mildvan, Donna ; Bazner, Suzane ; Streeck, Hendrik ; Alter, Galit ; Lifson, Jeffrey D ; Carrington, Mary ; Bosch, Ronald J ; Robbins, Gregory K ; Altfeld, Marcus2009 AugNat Med815
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.Sandler, Netanya G ; Zhang, Xinyan ; Bosch, Ronald J ; Funderburg, Nicholas T ; Choi, Andrew I ; Robinson, Janet K ; Fine, Derek M ; Coombs, Robert W ; Jacobson, Jeffrey M ; Landay, Alan L ; Douek, Daniel C ; Tressler, Randall ; Read, Sarah W ; Wilson, Cara C ; Deeks, Steven G ; Lederman, Michael M ; Gandhi, Rajesh T ; AIDS Clinical Trials2014 Nov 15J Infect Dis10210
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.Rosenberg, Eric S ; Graham, Barney S ; Chan, Ellen S ; Bosch, Ronald J ; Stocker, Vicki ; Maenza, Janine ; Markowitz, Martin ; Little, Susan ; Sax, Paul E ; Collier, Ann C ; Nabel, Gary ; Saindon, Suzanne ; Flynn, Theresa ; Kuritzkes, Daniel ; Barouch, Dan H ; AIDS Clinical Trials Group A5187 Team2010PLoS One55
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.Tenorio, Allan R ; Chan, Ellen S ; Bosch, Ronald J ; Macatangay, Bernard J C ; Read, Sarah W ; Yesmin, Suria ; Taiwo, Babafemi ; Margolis, David M ; Jacobson, Jeffrey M ; Landay, Alan L ; Wilson, Cara C ; A5286 Team2015 Mar 1J Infect Dis5211
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.Clark, Shauna A ; Shulman, Nancy S ; Bosch, Ronald J ; Mellors, John W2006 Apr 24AIDS720
Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.Gandhi, Rajesh T ; Bosch, Ronald J ; Aga, Evgenia ; Bedison, Margaret A ; Bastow, Barbara ; Schmitz, John L ; Siliciano, Janet D ; Siliciano, Robert F ; Eron, Joseph J ; Mellors, John W ; ACTG A5173 team2013Antivir Ther418
Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.Smurzynski, Marlene ; Wu, Kunling ; Benson, Constance A ; Bosch, Ronald J ; Collier, Ann C ; Koletar, Susan L2010 SepJ Acquir Immune Defic Syndr155
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment.Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald ; AIDS Clinical Trials Group A5132 Team2011 JunJ Interferon Cytokine Res631
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.Gandhi, Rajesh T ; O'Neill, David ; Bosch, Ronald J ; Chan, Ellen S ; Bucy, R Pat ; Shopis, Janet ; Baglyos, Lynn ; Adams, Elizabeth ; Fox, Lawrence ; Purdue, Lynette ; Marshak, Ann ; Flynn, Theresa ; Masih, Reena ; Schock, Barbara ; Mildvan, Donna ; Schlesinger, Sarah J ; Marovich, Mary A ; Bhardwaj, Nina ; Jacobson, Jeffrey M ; AIDS Clin2009 Oct 9Vaccine4327
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).Kilby, J Michael ; Bucy, R Pat ; Mildvan, Donna ; Fischl, Margaret ; Santana-Bagur, Jorge ; Lennox, Jeff ; Pilcher, Chris ; Zolopa, Andrew ; Lawrence, Jody ; Pollard, Richard B ; Habib, Raphaelle El ; Sahner, David ; Fox, Lawrence ; Aga, Evgenia ; Bosch, Ronald J ; Mitsuyasu, Ronald ; Adult AIDS Clinical Trials Group A5024 Protocol Team2006 Dec 15J Infect Dis12194
Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.Dykes, Carrie ; Mukherjee, A Lisa ; Bosch, Ronald J ; Connick, Elizabeth ; Volberding, Paul A ; Demeter, Lisa M2010 SepJ Acquir Immune Defic Syndr155
The prevalence and incidence of neurocognitive impairment in the HAART era.Robertson, Kevin R ; Smurzynski, Marlene ; Parsons, Thomas D ; Wu, Kunling ; Bosch, Ronald J ; Wu, Julia ; McArthur, Justin C ; Collier, Ann C ; Evans, Scott R ; Ellis, Ron J2007 Sep 12AIDS1421
Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.Bosch, Ronald J ; Bennett, Kara ; Collier, Ann C ; Zackin, Robert ; Benson, Constance A2007 Mar 1J Acquir Immune Defic Syndr344
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.Zheng, Lu ; Bosch, Ronald J ; Chan, Ellen S ; Read, Sarah ; Kearney, Mary ; Margolis, David M ; Mellors, John W ; Eron, Joseph J ; Gandhi, Rajesh T ; DS Clinical Trials Group (ACTG) A5244 Team2013Antivir Ther118
Plasma apolipoprotein L1 levels do not correlate with CKD.Bruggeman, Leslie A ; O'Toole, John F ; Ross, Michael D ; Madhavan, Sethu M ; Smurzynski, Marlene ; Wu, Kunling ; Bosch, Ronald J ; Gupta, Samir ; Pollak, Martin R ; Sedor, John R ; Kalayjian, Robert C2014 MarJ Am Soc Nephrol325
Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Vardhanabhuti, Saran ; Taiwo, Babafemi ; Kuritzkes, Daniel R ; Eron, Joseph J ; Bosch, Ronald J2015Antivir Ther120
Peripheral neuropathy in HIV: prevalence and risk factors.Evans, Scott R ; Ellis, Ronald J ; Chen, Huichao ; Yeh, Tzu-min ; Lee, Anthony J ; Schifitto, Giovanni ; Wu, Kunling ; Bosch, Ronald J ; McArthur, Justin C ; Simpson, David M ; Clifford, David B2011 Apr 24AIDS725
Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.Chen, Huichao ; Clifford, David B ; Deng, Lijuan ; Wu, Kunling ; Lee, Anthony J ; Bosch, Ronald J ; Riddler, Sharon A ; Ellis, Ronald J ; Evans, Scott R2013 DecJ Neurovirol619
Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay.Stewart, Paul ; Cachafeiro, Ada ; Napravnik, Sonia ; Eron, Joseph J ; Frank, Ian ; van der Horst, Charles ; Bosch, Ronald J ; Bettendorf, Daniel ; Bohlin, Peter ; Fiscus, Susan A2010 NovJ Clin Virol349
Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.Lee, Anthony J ; Bosch, Ronald J ; Evans, Scott R ; Wu, Kunling ; Harrison, Taylor ; Grant, Philip ; Clifford, David B2015 AprJ Neurovirol221
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.Ribaudo, Heather J ; Benson, Constance A ; Zheng, Yu ; Koletar, Susan L ; Collier, Ann C ; Lok, Judith J ; Smurzynski, Marlene ; Bosch, Ronald J ; Bastow, Barbara ; Schouten, Jeffrey T ; ACTG A5001/ALLRT Protocol Team2011 Apr 1Clin Infect Dis752
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.Gandhi, Rajesh T ; Bosch, Ronald J ; Aga, Evgenia ; Albrecht, Mary ; Demeter, Lisa M ; Dykes, Carrie ; Bastow, Barbara ; Para, Michael ; Lai, Jun ; Siliciano, Robert F ; Siliciano, Janet D ; Eron, Joseph J ; AIDS Clinical Trials Group A5173 Team2010 Jan 15J Infect Dis2201
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.Gandhi, Rajesh T ; Coombs, Robert W ; Chan, Ellen S ; Bosch, Ronald J ; Zheng, Lu ; Margolis, David M ; Read, Sarah ; Kallungal, Beatrice ; Chang, Ming ; Goecker, Erin A ; Wiegand, Ann ; Kearney, Mary ; Jacobson, Jeffrey M ; D'Aquila, Richard ; Lederman, Michael M ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials Group (ACTG) A52442012 Mar 1J Acquir Immune Defic Syndr359
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.Schacker, Timothy W ; Bosch, Ronald J ; Bennett, Kara ; Pollard, Richard ; Robbins, Gregory K ; Collier, Ann C ; Gulick, Roy M ; Spritzler, John ; Mildvan, Donna ; AIDS Clinical Trials Group2010 May 1J Acquir Immune Defic Syndr154
Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Swindells, Susan ; Jiang, Hongyu ; Mukherjee, A Lisa ; Winters, Mark ; Bosch, Ronald J ; Katzenstein, David2011 Mar-AprHIV Clin Trials212
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.Lok, Judith J ; Bosch, Ronald J ; Benson, Constance A ; Collier, Ann C ; Robbins, Gregory K ; Shafer, Robert W ; Hughes, Michael D ; ALLRT team2010 Jul 31AIDS1224
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.Gandhi, Rajesh T ; McMahon, Deborah K ; Bosch, Ronald J ; Lalama, Christina M ; Cyktor, Joshua C ; Macatangay, Bernard J ; Rinaldo, Charles R ; Riddler, Sharon A ; Hogg, Evelyn ; Godfrey, Catherine ; Collier, Ann C ; Eron, Joseph J ; Mellors, John W ; ACTG A5321 Team2017 AprPLoS Pathog413
Intracellular Casp8p41 content is inversely associated with CD4 T cell count.Cummins, Nathan W ; Jiang, Wei ; McGinty, John ; Bren, Gary D ; Bosch, Ronald J ; Landay, Alan ; Deeks, Steven G ; Martin, Jeffrey N ; Douek, Daniel ; Lederman, Michael M ; Brenchley, Jason ; Badley, Andrew D2010 Aug 15J Infect Dis3202
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials.Taylor, Lynn E ; Holubar, Marisa ; Wu, Kunling ; Bosch, Ronald J ; Wyles, David L ; Davis, John A ; Mayer, Kenneth H ; Sherman, Kenneth E ; Tashima, Karen T2011 Mar 15Clin Infect Dis652
Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.Park, You Jeong ; Etemad, Behzad ; Ahmed, Hayat ; Naranbhai, Vivek ; Aga, Evgenia ; Bosch, Ronald J ; Mellors, John W ; Kuritzkes, Daniel R ; Para, Michael ; Gandhi, Rajesh T ; Carrington, Mary ; Li, Jonathan Z2017Pathog Immun32
Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.Coban, Hamza ; Robertson, Kevin ; Smurzynski, Marlene ; Krishnan, Supriya ; Wu, Kunling ; Bosch, Ronald J ; Collier, Ann C ; Ellis, Ronald J2017 Jul 17AIDS1131
The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.Lok, Judith J ; Hunt, Peter W ; Collier, Ann C ; Benson, Constance A ; Witt, Mallory D ; Luque, Amneris E ; Deeks, Steven G ; Bosch, Ronald J2013 Aug 24AIDS1327
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.Zhang, Xinyan ; Hunt, Peter W ; Hammer, Scott M ; Cespedes, Michelle S ; Patterson, Kristine B ; Bosch, Ronald J2013 Mar-AprHIV Clin Trials214
HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.Kantor, Rami ; Bettendorf, Daniel ; Bosch, Ronald J ; Mann, Marita ; Katzenstein, David ; Cu-Uvin, Susan ; D'Aquila, Richard ; Frenkel, Lisa ; Fiscus, Susan ; Coombs, Robert ; ACTG A5077 Study Team2014PLoS One49
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.Sharaf, Radwa ; Lee, Guinevere Q ; Sun, Xiaoming ; Etemad, Behzad ; Aboukhater, Layla M ; Hu, Zixin ; Brumme, Zabrina L ; Aga, Evgenia ; Bosch, Ronald J ; Wen, Ying ; Namazi, Golnaz ; Gao, Ce ; Acosta, Edward P ; Gandhi, Rajesh T ; Jacobson, Jeffrey M ; Skiest, Daniel ; Margolis, David M ; Mitsuyasu, Ronald ; Volberding, Paul ; Connick, El2018 Aug 31J Clin Invest9128
HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.Besson, Guillaume J ; Lalama, Christina M ; Bosch, Ronald J ; Gandhi, Rajesh T ; Bedison, Margaret A ; Aga, Evgenia ; Riddler, Sharon A ; McMahon, Deborah K ; Hong, Feiyu ; Mellors, John W2014 Nov 1Clin Infect Dis959
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Mollan, Katie ; Daar, Eric S ; Sax, Paul E ; Balamane, Maya ; Collier, Ann C ; Fischl, Margaret A ; Lalama, Christina M ; Bosch, Ronald J ; Tierney, Camlin ; Katzenstein, David ; AIDS Clinical Trials Group Study A5202 Team2012 Dec 15J Infect Dis12206
HIV peripheral neuropathy progression: protection with glucose-lowering drugs?Evans, Scott R ; Lee, Anthony J ; Ellis, Ronald J ; Chen, Huichao ; Wu, Kunling ; Bosch, Ronald J ; Clifford, David B2012 OctJ Neurovirol518
Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication.Chang, J Judy ; Woods, Matt ; Lindsay, Robert J ; Doyle, Erin H ; Griesbeck, Morgane ; Chan, Ellen S ; Robbins, Gregory K ; Bosch, Ronald J ; Altfeld, Marcus2013 Sep 1J Infect Dis5208
Factors associated with remaining on initial randomized efavirenz-containing regimens.Smurzynski, Marlene ; Wu, Kunling ; Schouten, Jeffrey T ; Lok, Judith J ; Bosch, Ronald J ; Taiwo, Babafemi ; Johnson, Victoria Anne ; Collier, Ann C2013 Jul 31AIDS1227
Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.Zheng, Lu ; Taiwo, Babafemi ; Gandhi, Rajesh T ; Hunt, Peter W ; Collier, Ann C ; Flexner, Charles ; Bosch, Ronald J2014 Oct 1J Acquir Immune Defic Syndr267
The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era.Gupta, Samir K ; Smurzynski, Marlene ; Franceschini, Nora ; Bosch, Ronald J ; Szczech, Lynda A ; Kalayjian, Robert C ; AIDS Clinical Trials Group Longitudinal Linked Randomized Trials Study Team2009Antivir Ther414
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.Smurzynski, Marlene ; Wu, Kunling ; Letendre, Scott ; Robertson, Kevin ; Bosch, Ronald J ; Clifford, David B ; Evans, Scott ; Collier, Ann C ; Taylor, Michael ; Ellis, Ronald2011 Jan 28AIDS325
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5Nixon, Daniel E ; Bosch, Ronald J ; Chan, Ellen S ; Funderburg, Nicholas T ; Hodder, Sally ; Lake, Jordan E ; Lederman, Michael M ; Klingman, Karin L ; Aberg, Judith A ; AIDS Clinical Trials Group Study A5275 Team2017 Jan - FebJ Clin Lipidol111
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.Gandhi, Rajesh T ; Zheng, Lu ; Bosch, Ronald J ; Chan, Ellen S ; Margolis, David M ; Read, Sarah ; Kallungal, Beatrice ; Palmer, Sarah ; Medvik, Kathy ; Lederman, Michael M ; Alatrakchi, Nadia ; Jacobson, Jeffrey M ; Wiegand, Ann ; Kearney, Mary ; Coffin, John M ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials Group A5244 team2010PLoS Med87
The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.Eron, Joseph J ; Bosch, Ronald J ; Bettendorf, Daniel ; Petch, Leslie ; Fiscus, Susan ; Frank, Ian ; Adult Clinical Trials Group 307 Protocol Team2007 Jun 1J Acquir Immune Defic Syndr245
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.Bakshi, Rahul P ; Hamzeh, Fayez ; Frank, Ian ; Eron, Joseph J ; Bosch, Ronald J ; Rosenkranz, Susan L ; Cramer, Yoninah S ; Ussery, Michael ; Flexner, Charles2007 NovAIDS Res Hum Retroviruses1123
Effect of early versus deferred antiretroviral therapy for HIV on survival.Kitahata, Mari M ; Gange, Stephen J ; Abraham, Alison G ; Merriman, Barry ; Saag, Michael S ; Justice, Amy C ; Hogg, Robert S ; Deeks, Steven G ; Eron, Joseph J ; Brooks, John T ; Rourke, Sean B ; Gill, M John ; Bosch, Ronald J ; Martin, Jeffrey N ; Klein, Marina B ; Jacobson, Lisa P ; Rodriguez, Benigno ; Sterling, Timothy R ; Kirk, Grego2009 Apr 30N Engl J Med18360
Drug-resistant virus has reduced ability to induce immune activation.Wang, Rui ; Bosch, Ronald J ; Benson, Constance A ; Lederman, Michael M2012 Dec 1J Acquir Immune Defic Syndr461
Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring.Schnitzer, Mireille E ; Lok, Judith J ; Bosch, Ronald J2016 JanBiostatistics117
Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.Weinberg, Adriana ; Tierney, Camlin ; Kendall, Michelle A ; Bosch, Ronald J ; Patterson-Bartlett, Julie ; Erice, Alejo ; Hirsch, Martin S ; Polsky, Bruce ; AIDS Clinical Trials Group 360 Team2006 Feb 15J Infect Dis4193
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.Gandhi, Monica ; Gandhi, Rajesh T ; Stefanescu, Andrei ; Bosch, Ronald J ; Cyktor, Joshua C ; Horng, Howard ; Louie, Alexander ; Phung, Nhi ; Eron, Joseph J ; Hogg, Evelyn ; Macatangay, Bernard J C ; Hensel, Christopher ; Fletcher, Courtney V ; Mellors, John W ; McMahon, Deborah K ; A5321 Team2018 Jun 20J Infect Dis2218
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.Namazi, Golnaz ; Fajnzylber, Jesse M ; Aga, Evgenia ; Bosch, Ronald J ; Acosta, Edward P ; Sharaf, Radwa ; Hartogensis, Wendy ; Jacobson, Jeffrey M ; Connick, Elizabeth ; Volberding, Paul ; Skiest, Daniel ; Margolis, David ; Sneller, Michael C ; Little, Susan J ; Gianella, Sara ; Smith, Davey M ; Kuritzkes, Daniel R ; Gulick, Roy M ; Mello2018 Nov 05J Infect Dis12218
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald2010AIDS Res Ther7
Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.Riddler, Sharon A ; Aga, Evgenia ; Bosch, Ronald J ; Bastow, Barbara ; Bedison, Margaret ; Vagratian, David ; Vaida, Florin ; Eron, Joseph J ; Gandhi, Rajesh T ; Mellors, John W ; ACTG A5276s Protocol Team2016 Feb 15J Infect Dis4213
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Gange, Stephen J ; Kitahata, Mari M ; Saag, Michael S ; Bangsberg, David R ; Bosch, Ronald J ; Brooks, John T ; Calzavara, Liviana ; Deeks, Steven G ; Eron, Joseph J ; Gebo, Kelly A ; Gill, M John ; Haas, David W ; Hogg, Robert S ; Horberg, Michael A ; Jacobson, Lisa P ; Justice, Amy C ; Kirk, Gregory D ; Klein, Marina B ; Martin, Jeffrey 2007 AprInt J Epidemiol236
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.Gay, Cynthia L ; Bosch, Ronald J ; Ritz, Justin ; Hataye, Jason M ; Aga, Evgenia ; Tressler, Randall L ; Mason, Stephen W ; Hwang, Carey K ; Grasela, Dennis M ; Ray, Neelanjana ; Cyktor, Josh C ; Coffin, John M ; Acosta, Edward P ; Koup, Richard A ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials 5326 Study Team2017 Jun 01J Infect Dis11215
Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment.Bosch, Ronald J ; Wang, Rui ; Vaida, Florin ; Lederman, Michael M ; Albrecht, Mary A2006 Dec 1J Acquir Immune Defic Syndr443
Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.Angelidou, Konstantia ; Hunt, Peter W ; Landay, Alan L ; Wilson, Cara C ; Rodriguez, Benigno ; Deeks, Steven G ; Bosch, Ronald J ; Lederman, Michael M2018 Jun 20J Infect Dis2218
CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.Taiwo, Babafemi ; Hunt, Peter W ; Gandhi, Rajesh T ; Ellingson, Andrew ; McKenna, Matthew ; Jacobson, Jeffrey M ; Gripshover, Barbara ; Bosch, Ronald J2013 May 1J Acquir Immune Defic Syndr163
CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.Henrich, Timothy J ; Hanhauser, Emily ; Harrison, Linda J ; Palmer, Christine D ; Romero-Tejeda, Marisol ; Jost, Stephanie ; Bosch, Ronald J ; Kuritzkes, Daniel R2016 Mar 1J Infect Dis5213
Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.Treasure, Graham C ; Aga, Evgenia ; Bosch, Ronald J ; Mellors, John W ; Kuritzkes, Daniel R ; Para, Michael ; Gandhi, Rajesh T ; Li, Jonathan Z2016 Jul 1J Acquir Immune Defic Syndr372
Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy.Palermo, Brandon ; Bosch, Ronald J ; Bennett, Kara ; Jacobson, Jeffrey M2011 Jul-AugHIV Clin Trials412
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals.Hoffman, Risa M ; Jamieson, Beth D ; Bosch, Ronald J ; Currier, Judith ; Kitchen, Christina M R ; Schmid, Ingrid ; Zhu, Yuda ; Bennett, Kara ; Mitsuyasu, Ronald2011 OctJ Clin Immunol531
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.Connick, Elizabeth ; Bosch, Ronald J ; Aga, Evgenia ; Schlichtemeier, Rick ; Demeter, Lisa M ; Volberding, Paul ; ACTG 709 Team2011 Sep 1J Acquir Immune Defic Syndr158
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.Brown, Todd T ; Tassiopoulos, Katherine ; Bosch, Ronald J ; Shikuma, Cecilia ; McComsey, Grace A2010 OctDiabetes Care1033
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.Volberding, Paul ; Demeter, Lisa ; Bosch, Ronald J ; Aga, Evgenia ; Pettinelli, Carla ; Hirsch, Martin ; Vogler, Mary ; Martinez, Ana ; Little, Susan ; Connick, Elizabeth ; ACTG 371 Team2009 Sep 24AIDS1523
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.Smurzynski, Marlene ; Collier, Ann C ; Koletar, Susan L ; Bosch, Ronald J ; Wu, Kunling ; Bastow, Barbara ; Benson, Constance A2008 Jul-AugHIV Clin Trials49